ArticlemedRxiv : the preprint server for health sciences2025

A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer.

Mark R Kelley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.